Albumin administration – what is the evidence of clinical benefit? A systematic review of randomized controlled trials
Authors:
- R. J. NavickisRNR. J. Navickis
- M. M. WilkesMWM. M. Wilkes
- 1 November 2003
- journal article
- review article
- Published by Wolters Kluwer Health
- Vol. 20 (10) , 771-793
Abstract
The advantages of albumin over less costly alternative fluids continue to be debated. Meta-analyses focusing on survival have been inconclusive, and other clinically relevant end-points have not been systematically addressed. We sought to determine whether albumin confers significant clinical benefit in acute illness compared with other fluid regimens. Database searches (MEDLINE, EMBASE, Cochrane Library) and other methods were used to identify randomized controlled trials comparing albumin with crystalloid, artificial colloid, no albumin or lower-dose albumin. Major findings for all end-points were extracted and summarized. A quantitative meta-analysis was not attempted. Seventy-nine randomized trials with a total of 4755 patients were included. No significant treatment effects were detectable in 20/79 (25%) trials. In cardiac surgery, albumin administration resulted in lower fluid requirements, higher colloid oncotic pressure, reduced pulmonary oedema with respiratory impairment and greater haemodilution compared with crystalloid and hydroxyethylstarch increased postoperative bleeding. In non-cardiac surgery, fluid requirements, and pulmonary and intestinal oedema were decreased by albumin compared with crystalloid. In hypoalbuminaemia, higher doses of albumin reduced morbidity. In ascites, albumin reduced haemodynamic derangements, morbidity and length of stay and improved survival after spontaneous bacterial peritonitis. In sepsis, albumin decreased pulmonary oedema and respiratory dysfunction compared with crystalloid, while hydroxyethylstarch induced abnormalities of haemostasis. Complications were lowered by albumin compared with crystalloid in burn patients. Albumin-containing therapeutic regimens improved outcomes after brain injury. Albumin can bestow benefit in diverse clinical settings. Further trials are warranted to delineate optimal fluid regimens, in particular indications.Keywords
This publication has 88 references indexed in Scilit:
- Understanding the Treatment Preferences of Seriously Ill PatientsNew England Journal of Medicine, 2002
- Patient Survival after Human Albumin AdministrationAnnals of Internal Medicine, 2001
- Safety of human albumin based on spontaneously reported serious adverse eventsCritical Care Medicine, 2001
- The Good, the Bad, and the Ugly: Should We Completely Banish Human Albumin from Our Intensive Care Units? [RETRACTED]Anesthesia & Analgesia, 2000
- Cochrane Injuries Group Albumin ReviewersWhy albumin may not workBMJ, 1998
- Comparison of hemodynamic, pulmonary, and renal effects of use of three types of fluids after major surgical procedures on the abdominal aortaCritical Care Medicine, 1979
- The Effect of Hemodilution with Albumin or Ringer's Lactate on Water Balance and Blood Use in Open-Heart SurgeryThe Annals of Thoracic Surgery, 1978
- Cardiac Output and Pulmonary Wedge PressureArchives of Surgery, 1977
- PLASMA PROTEIN STUDIES ON NORMAL NEWBORN AND PREMATURE INFANTSA.M.A. American Journal of Diseases of Children, 1948
- CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. VII. CONCENTRATED HUMAN SERUM ALBUMIN 123Journal of Clinical Investigation, 1944